All In Biotech

Drug Trial Radar · NCT06547489

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Phase 2, Multicenter, Randomized, Double-blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder in Adults

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Syndeio Biosciences, IncIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Conditions

  • Major Depressive Disorder

Interventions

  • ZelquistinelDrug

    Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Hamilton Depression Rating Scale-17 (HDRS-17) score compared to placeboTime frame: Change in score from predose baseline to end of week 6

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham-Huntsville

    Huntsville, Alabama · Active not recruiting

  • Wr-Pri, Llc

    Encino, California · Withdrawn

  • Irvine Clinical Research

    Irvine, California · Recruiting

  • CalNeuro Research Group

    Los Angeles, California · Recruiting

  • Pacific Clinical Research Management Group LLC

    Upland, California · Terminated

  • Sunwise Clinical Research LLC

    Walnut Creek, California · Recruiting

  • MCB Clinical Research Centers, Inc.

    Colorado Springs, Colorado · Recruiting

  • Mountain View Clinical Research

    Denver, Colorado · Recruiting

  • University of Connecticut School of Medicine Psychiatry Department

    Farmington, Connecticut · Recruiting

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida · Recruiting

  • D&H Pompano Research Center, LLC

    Margate, Florida · Recruiting

  • Premier Clinical Research Institute, Inc.

    Miami, Florida · Recruiting

  • Miami Dade Medical Research Institute

    Miami, Florida · Recruiting

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida · Recruiting

  • CenExel iRS (iResearch Savannah)

    Savannah, Georgia · Recruiting

  • Revive Research Institute

    Elgin, Illinois · Withdrawn

  • KUMC-Wichita

    Wichita, Kansas · Withdrawn

  • Quantum Research Associates Corp.

    Louisville, Kentucky · Active not recruiting

  • Boston Clinical Trials

    Boston, Massachusetts · Withdrawn

  • Mayflower Clinical

    Russells Mills, Massachusetts · Recruiting

  • Vector Clinical Trials

    Las Vegas, Nevada · Active not recruiting

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York · Recruiting

  • Insight Clinical Trials LLC

    Independence, Ohio · Recruiting

  • Sooner Clinical Research, Inc.

    Oklahoma City, Oklahoma · Withdrawn

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania · Recruiting

  • Clinical Neuroscience Solutions, Inc.

    Memphis, Tennessee · Withdrawn

  • Austin Clinical Trial Partners

    Austin, Texas · Recruiting

  • InSite Clinical Research, LLC

    DeSoto, Texas · Recruiting

  • Baylor College of Medicine, Psychiatry and Behavioral Sciences

    Houston, Texas · Withdrawn

  • Clinical Trials of Texas LLC

    San Antonio, Texas · Withdrawn

  • Grayline Research Center

    Wichita Falls, Texas · Recruiting

  • Andes Clinical Research

    Orem, Utah · Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington · Withdrawn

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.